| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus Diabetes Control and Complications Trial Research Group N Engl j Med 1993 (329), 977-986, 1993 | 27380 | 1993 |
| Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, S Hantel, ... New England Journal of Medicine 373 (22), 2117-2128, 2015 | 13511 | 2015 |
| Implications of the United Kingdom prospective diabetes study American Diabetes Association Diabetes Care 21 (12), 2180-2184, 1998 | 7947* | 1998 |
| Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions DM Nathan, M Bayless, P Cleary, S Genuth, R Gubitosi-Klug, JM Lachin, ... Diabetes 62 (12), 3976-3986, 2013 | 7377* | 2013 |
| Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes Diabetes Control and Complications Trial N Engl J Med 2005 (353), 2643-2653, 2005 | 6922* | 2005 |
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy SE Kahn, SM Haffner, MA Heise, WH Herman, RR Holman, NP Jones, ... New England Journal of Medicine 355 (23), 2427-2443, 2006 | 4173 | 2006 |
| Empagliflozin and progression of kidney disease in type 2 diabetes C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, ... New England Journal of Medicine 375 (4), 323-334, 2016 | 3904 | 2016 |
| Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes JB Green, MA Bethel, PW Armstrong, JB Buse, SS Engel, J Garg, R Josse, ... New England Journal of Medicine 373 (3), 232-242, 2015 | 3246 | 2015 |
| Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes DM Nathan, PA Cleary, JY Backlund, SM Genuth, JM Lachin, TJ Orchard, ... N Engl J Med 353 (25), 2643-2653, 2005 | 2606* | 2005 |
| Effect of weight loss with lifestyle intervention on risk of diabetes RF Hamman, RR Wing, SL Edelstein, JM Lachin, GA Bray, L Delahanty, ... Diabetes care 29 (9), 2102-2107, 2006 | 1705 | 2006 |
| Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy Diabetes Control and Complications Trial, ... The New England Journal of Medicine 342 (6), 381, 2000 | 1464* | 2000 |
| Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. JM Lachin, S Genuth, P Cleary, MD Davis, DM Nathan The New England journal of medicine 342 (6), 381-389, 2000 | 1464 | 2000 |
| Introduction to sample size determination and power analysis for clinical trials JM Lachin Controlled clinical trials 2 (2), 93-113, 1981 | 1283 | 1981 |
| Rituximab, B-lymphocyte depletion, and preservation of beta-cell function MD Pescovitz, CJ Greenbaum, H Krause-Steinrauf, DJ Becker, ... New England Journal of Medicine 361 (22), 2143-2152, 2009 | 1163 | 2009 |
| Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial D Fitchett, B Zinman, C Wanner, JM Lachin, S Hantel, A Salsali, ... European heart journal 37 (19), 1526-1534, 2016 | 1110 | 2016 |
| Intensive diabetes therapy and carotid intima–media thickness in type 1 diabetes mellitus Diabetes Control and Complications Trial, ... The New England journal of medicine 348 (23), 2294, 2003 | 1086 | 2003 |
| Randomization in Clinical Trials WF Rosenberg, JM Lachin New York: John Wiley & Sons, 2002 | 1006* | 2002 |
| Randomization in clinical trials: theory and practice WF Rosenberger, JM Lachin John Wiley & Sons, 2004 | 991* | 2004 |
| Effects of insulin in relatives of patients with type 1 diabetes mellitus JS Skyler, D Brown, HP Chase, E Collier, C Cowie, GS Eisenbarth, ... New England Journal of Medicine 346 (22), 1685-1691, 2002 | 899* | 2002 |
| Statistical considerations in the intent-to-treat principle JM Lachin Controlled clinical trials 21 (3), 167-189, 2000 | 780 | 2000 |
Odd Erik JohansenNestlé Health Science, Bærum Hospital, Oslo University Hospital確認したメール アドレス: nestle.com
